Phase II trial evaluating Gleevec (imatinib mesylate formerly known as STI571) in patients with anaplastic thyroid cancer.

Trial Profile

Phase II trial evaluating Gleevec (imatinib mesylate formerly known as STI571) in patients with anaplastic thyroid cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2014

At a glance

  • Drugs Imatinib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2011 Planned end date changed from 1 Apr 2005 to 1 Aug 2010 as reported by ClinicalTrials.gov
    • 23 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 19 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top